These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 9147006)
1. Variations in DNA subtype and antifungal susceptibility among clinical isolates of Candida tropicalis. Zhang J; Hollis RJ; Pfaller MA Diagn Microbiol Infect Dis; 1997 Mar; 27(3):63-7. PubMed ID: 9147006 [TBL] [Abstract][Full Text] [Related]
2. National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Pfaller MA; Messer SA; Houston A; Rangel-Frausto MS; Wiblin T; Blumberg HM; Edwards JE; Jarvis W; Martin MA; Neu HC; Saiman L; Patterson JE; Dibb JC; Roldan CM; Rinaldi MG; Wenzel RP Diagn Microbiol Infect Dis; 1998 May; 31(1):289-96. PubMed ID: 9597389 [TBL] [Abstract][Full Text] [Related]
3. Antifungal activity of a new triazole, D0870, compared with four other antifungal agents tested against clinical isolates of Candida and Torulopsis glabrata. Pfaller MA; Bale MJ; Buschelman B; Rhomberg P Diagn Microbiol Infect Dis; 1994 Jun; 19(2):75-80. PubMed ID: 7805359 [TBL] [Abstract][Full Text] [Related]
4. Variations in DNA subtype, antifungal susceptibility, and slime production among clinical isolates of Candida parapsilosis. Pfaller MA; Messer SA; Hollis RJ Diagn Microbiol Infect Dis; 1995 Jan; 21(1):9-14. PubMed ID: 7789100 [TBL] [Abstract][Full Text] [Related]
5. Strain variation among and antifungal susceptibilities of isolates of Candida krusei. Berrouane YF; Hollis RJ; Pfaller MA J Clin Microbiol; 1996 Jul; 34(7):1856-8. PubMed ID: 8784612 [TBL] [Abstract][Full Text] [Related]
6. Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Pfaller MA; Messer SA; Hollis RJ Diagn Microbiol Infect Dis; 1994 Nov; 20(3):127-33. PubMed ID: 7874879 [TBL] [Abstract][Full Text] [Related]
7. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Marco F; Pfaller MA; Messer S; Jones RN Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278 [TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole. Martín E; Parras P; Lozano MC Chemotherapy; 1992; 38(5):335-9. PubMed ID: 1337508 [TBL] [Abstract][Full Text] [Related]
9. Species distribution, antifungal susceptibility and clonal relatedness of Candida isolates from patients in neonatal and pediatric intensive care units at a medical center in Turkey. Kuzucu C; Durmaz R; Otlu B; Aktas E; Gulcan H; Cizmeci Z New Microbiol; 2008 Jul; 31(3):401-8. PubMed ID: 18843896 [TBL] [Abstract][Full Text] [Related]
10. DNA macrorestriction profiles and antifungal susceptibility of Candida (Torulopsis) glabrata. Cormican MG; Hollis RJ; Pfaller MA Diagn Microbiol Infect Dis; 1996 Jun; 25(2):83-7. PubMed ID: 8882894 [TBL] [Abstract][Full Text] [Related]
11. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Pfaller MA; Messer S; Jones RN Antimicrob Agents Chemother; 1997 Feb; 41(2):233-5. PubMed ID: 9021172 [TBL] [Abstract][Full Text] [Related]
12. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Marco F; Pfaller MA; Messer SA; Jones RN Diagn Microbiol Infect Dis; 1998 Sep; 32(1):33-7. PubMed ID: 9791755 [TBL] [Abstract][Full Text] [Related]
13. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. Panizo MM; Reviákina V; Dolande M; Selgrad S Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308 [TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibility of Candida isolates at the American University of Beirut Medical Center. Araj GF; Daher NK; Tabbarah ZA Int J Antimicrob Agents; 1998 Nov; 10(4):291-6. PubMed ID: 9916903 [TBL] [Abstract][Full Text] [Related]
15. Oral Candida isolates among HIV-infected subjects in Nigeria. Nweze EI; Ogbonnaya UL J Microbiol Immunol Infect; 2011 Jun; 44(3):172-7. PubMed ID: 21524610 [TBL] [Abstract][Full Text] [Related]
16. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of amphotericin B, flucytosine and fluconazole against yeasts causing bloodstream infections. Berenguer J; Fernández-Baca V; Sánchez R; Bouza E Eur J Clin Microbiol Infect Dis; 1995 Apr; 14(4):362-5. PubMed ID: 7649205 [TBL] [Abstract][Full Text] [Related]
18. Epidemiology of candidemia in a Turkish tertiary care hospital. Bakir M; Cerikcioglu N; Barton R; Yagci A APMIS; 2006 Sep; 114(9):601-10. PubMed ID: 16948812 [TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution method. Pfaller MA; Barry AL Mycopathologia; 1995; 130(1):3-9. PubMed ID: 7666925 [TBL] [Abstract][Full Text] [Related]
20. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. St-Germain G; Laverdière M; Pelletier R; Bourgault AM; Libman M; Lemieux C; Noël G J Clin Microbiol; 2001 Mar; 39(3):949-53. PubMed ID: 11230409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]